Nateglinide Route: Stepwise Transformation of D-Phe-OMe Hydrochloride Through N-Acylation and Controlled Ester Hydrolysis

The D-phenylalanine methyl ester hydrochloride intermediate is converted to the free amino ester by suspending the salt in dichloromethane at 5 volumes relative to starting mass and introducing aqueous sodium bicarbonate (1.2 molar equivalents) at 0–5°C. The biphasic neutralization extracts D-Phe-OMe into the organic layer with transfer efficiency exceeding 98% when agitation is maintained at 50–60 rpm in a glass-lined jacketed reactor equipped with a PTFE-coated anchor agitator. The organic phase is separated, and 1.1 molar equivalents of triethylamine is charged as acid scavenger. N-Acylation proceeds with trans-4-isopropylcyclohexanecarbonyl chloride at 1.05 molar equivalents, added as a dilute dichloromethane solution over 90–120 minutes while the batch temperature is held strictly at 0–5°C. Temperature excursions above 8°C during acyl chloride addition are consistently associated with a 0.3–0.5% increase in the undesired L-antipode epimer peak on chiral HPLC, a batch-to-batch variance pattern documented across multiple manufacturing campaigns. Reaction completion is confirmed when residual starting ester falls below 1.0% by peak area on a C18 column with acetonitrile and 0.1% phosphoric acid gradient elution. The quench sequence uses 1 M hydrochloric acid at 2 volumes followed by saturated sodium chloride to strip residual triethylamine hydrochloride, after which the organic phase is concentrated under reduced pressure at a jacket temperature not exceeding 40°C.

The isolated N-acylated methyl ester is redissolved in methanol at 3 volumes, and 2 M aqueous sodium hydroxide (1.5 molar equivalents) is introduced over 30 minutes while the batch temperature is controlled at 20–25°C. The hydrolysis window represents the most critical processing parameter: above 30°C, the α-carbon of the D-Phe residue undergoes measurable epimerization through enolate formation, with chiral purity declining from ≥99.5% ee to below 97% ee within 4 hours. The reaction is monitored by HPLC until the intermediate ester falls below 0.5% by area. Methanol is vacuum-distilled at ≤45°C, water is added at 3 volumes, and neutral impurities are extracted with methyl tert-butyl ether at 2 × 2 volumes. The aqueous sodium nateglinide solution is acidified with 6 M hydrochloric acid to pH 2.0–2.5 at 10–15°C, precipitating nateglinide as a white solid. The slurry is stirred for 1 hour at 5–10°C, filtered through a 316L stainless steel nutsche filter under 0.5–1.0 bar nitrogen pressure, washed with chilled purified water, and dried under vacuum at 40–45°C to constant weight. Documented batch yields for this sequence fall within 78–83% after recrystallization from ethyl acetate/n-heptane, with residual dichloromethane consistently below the ICH Q3C Class 2 limit of 600 ppm and residual methanol below 3000 ppm.

Regulatory alignment for this pathway references ICH Q7 sections 7.3 (material handling and control), 8.1 (process validation lifecycle), and 9.1 (starting material acceptance). Chiral purity is determined by HPLC on a Chiralpak AD-H column with n-hexane/ethanol (85:15 v/v) containing 0.1% trifluoroacetic acid, under conditions specified in USP general chapter <621>. Elemental impurities are controlled per ICH Q3D with ICP-MS limit values for Class 1 elements. The following parameter control matrix summarizes the documented process envelope.

Production-scale synthesis of somatostatin analogs, specifically octreotide, employs D-Phe-OMe·HCl as the source of the N-terminal D-phenylalanine residue. The methyl ester hydrochloride is first converted to the corresponding Fmoc- or Boc-protected D-Phe derivative by treatment with di-tert-butyl dicarbonate (1.1 molar equivalents) and triethylamine (1.5 molar equivalents) in dichloromethane at ambient temperature for 4–6 hours, followed by selective ester hydrolysis with lithium hydroxide (1.2 molar equivalents) in tetrahydrofuran/water (3:1 v/v) at 0–5°C for 2 hours. The resulting protected D-phenylalanine acid is then coupled to the growing peptide chain using HBTU (1.1 molar equivalents) and N,N-diisopropylethylamine (2.2 molar equivalents) in anhydrous N,N-dimethylformamide at 0°C for 30 minutes, followed by warming to 20–25°C for 2–4 hours. Documented coupling yields for the N-terminal D-Phe residue in octreotide fragment assemblies range from 85–92% when monitored by HPLC on a C18 column with UV detection at 220 nm. The terminal product, octreotide (H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-ol, cyclic disulfide), is a parenteral peptide API with a USP-NF monograph and a European Pharmacopoeia monograph; the D-Phe N-terminal residue confers resistance to aminopeptidase degradation, extending plasma half-life relative to native somatostatin. Compliance for peptide APIs intended for injection requires adherence to ICH Q7, ICH Q3C for residual solvent limits (dimethylformamide Class 2 limit 880 ppm; dichloromethane 600 ppm), and USP general chapters <1> (injections) and <85> (bacterial endotoxins test).

What Limits the Utility of D-Phe-OMe as a Chiral Derivatizing Agent in Routine Enantiomeric Excess Determination?

D-Phe-OMe in its free-base form is employed as a chiral derivatizing agent for the chromatographic and NMR determination of enantiomeric excess of chiral carboxylic acids, including profens, β-amino acid precursors, and certain enzyme transformation products. The derivatization protocol involves activation of the target carboxylic acid with 1.2 molar equivalents of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride in anhydrous N,N-dimethylformamide at 0–5°C, with 0.5 molar equivalents of 1-hydroxybenzotriazole hydrate as additive and 1.5 molar equivalents of D-Phe-OMe free base. The coupling proceeds for 1–2 hours at 0–5°C and forms diastereomeric amides that are separable by reversed-phase HPLC using a C18 stationary phase, acetonitrile/water gradient with 0.1% trifluoroacetic acid, and UV detection at 254 nm. A resolution factor (Rs) of at least 1.5 is required for accurate integration, per ICH Q2(R2) methodology. For ¹H NMR analysis, the methoxy singlet of D-Phe-OMe derivatives typically appears between 3.60–3.70 ppm; diastereomeric shift differences (Δδ) of 0.02–0.05 ppm are reported depending on the chiral acid structure, enabling direct integration of the diastereomeric pairs without physical separation. The primary operational limitation of this method is the sensitivity of the derivatization to trace moisture: water content in the solvent above 0.05% by Karl Fischer titration (USP <921>) reduces coupling efficiency through carbodiimide hydrolysis, producing N-acylurea by-products that co-elute with the diastereomeric peaks. Method validation documentation per ICH Q14 includes specificity against the underivatized acid, linearity over 0.1–10 mg/mL, and recovery assessments from spiked matrix samples. Terminal deliverables for this application are validated analytical procedures filed in CMC sections of regulatory submissions for chiral drug substance characterization.

An additional application of D-Phe-OMe·HCl arises in stereochemical control experiments for protease kinetic assays and in preparative-scale enzymatic resolution. α-Chymotrypsin (EC 3.4.21.1) hydrolyzes L-Phe-OMe with documented specificity, while the D-antipode remains unhydrolyzed under standard assay conditions (25°C, pH 7.8, 0.05 M Tris-HCl). D-Phe-OMe therefore functions as a non-hydrolyzable stereochemical probe to distinguish true enzyme-mediated amide bond cleavage from non-specific background hydrolysis or autocatalytic degradation in assay buffers. When racemic Phe-OMe·HCl (100 g/L) is subjected to α-chymotrypsin immobilized on controlled-pore glass in a stirred tank reactor at 37°C for 4–6 hours, enzymatic conversion is intentionally limited to 50% of the racemate. At conversions exceeding 50%, the enantiomeric excess of the recovered D-Phe-OMe degrades from ≥99% ee to below 95% ee as residual L-Phe-OMe is progressively depleted, a kinetic boundary defining the practical yield ceiling of the resolution. The recovered D-Phe-OMe is isolated by extraction with methyl tert-butyl ether at pH 8–9 and may be re-salted with hydrogen chloride gas to regenerate the hydrochloride salt. Published kinetic data for D-Phe-OMe inhibition constants against α-chymotrypsin is limited; available competitive inhibition studies report binding consistent with occupancy of the aromatic specificity pocket without turnover, but specific Ki values for this exact substrate configuration are not well established across published literature. Laboratory method transfer for this application requires ISO/IEC 17025:2017 documentation of enzyme activity verification, substrate purity certification, and batch-to-batch reproducibility of the immobilized enzyme support.

Oxazolidinone Auxiliary Synthesis from the Methyl Ester Hydrochloride

D-Phe-OMe·HCl is reduced to D-phenylalaninol in anhydrous tetrahydrofuran under nitrogen using lithium aluminum hydride at 2.0 molar equivalents, with addition at 0°C followed by reflux for 2 hours. Standard Fieser quench conditions (water, 15% sodium hydroxide, water in a 1:1:3 volume ratio) or Rochelle salt solutions are used to decompose the aluminum complex. D-Phenylalaninol is isolated in 70–85% yield after crystallization from ethyl acetate/n-hexane. The amino alcohol is then cyclized with diethyl carbonate (1.2 molar equivalents) in refluxing toluene containing catalytic sodium ethoxide (0.1 molar equivalents) to yield (R)-4-benzyl-1,3-oxazolidin-2-one, the Evans chiral auxiliary in its R-configuration. Cyclization yields of 80–90% are documented when water generated during the reaction is removed by azeotropic distillation. The (R)-auxiliary is the enantiomeric counterpart to the L-Phe-derived (S)-4-benzyl-2-oxazolidinone and enables access to the opposite absolute configuration in asymmetric aldol, alkylation, and conjugated addition reactions. N-Acylation of the auxiliary with propionyl chloride (1.1 molar equivalents) in the presence of triethylamine at 0°C generates the N-propionyl oxazolidinone, which undergoes titanium tetrachloride-mediated aldol addition to cinnamaldehyde (1.2 molar equivalents) with diisopropylethylamine (1.5 molar equivalents) at −78°C, delivering diastereomeric ratios typically above 95:5 when the reaction is quenched with saturated ammonium chloride at −78°C before warming. Terminal products of this application are chiral non-racemic synthetic intermediates required for API synthesis in cases where the (S)-auxiliary cannot be used due to substrate stereoselectivity requirements. Process safety for the lithium aluminum hydride reduction requires ATEX 2014/34/EU compliance for hydrogen evolution and thermal management; residual tetrahydrofuran in the isolated amino alcohol must be controlled below the ICH Q3C Class 2 limit of 720 ppm if the material advances to an API manufacturing step.

D-Phe-OMe·HCl is distributed as a qualified reference standard for chiral HPLC and achiral HPLC system suitability verification in analytical laboratories supporting pharmaceutical intermediate manufacturing. Certificates of analysis document assigned purity values traceable to ISO 17034:2016 and ISO/IEC 17025:2017, with chiral purity determined on a polysaccharide-based chiral stationary phase (typical specification ≥99.5% ee), achiral purity by reversed-phase HPLC at 210 nm (typical specification ≥99.0% area), water content by Karl Fischer titration per USP <921>, and elemental impurity screening by ICP-MS per ICH Q3D.

When D-Phe-OMe Replaces Free D-Phenylalanine in Direct Thrombin Inhibitor Fragment Assembly

Bivalirudin, the synthetic direct thrombin inhibitor with the polypeptide sequence D-Phe-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu, requires an N-terminal D-phenylalanine residue for thrombin exosite occupancy and resistance to circulating aminopeptidases. D-Phe-OMe·HCl serves as the precursor for the N-terminal D-Phe residue in fragment-based or hybrid solid-phase solution-phase synthesis strategies. The hydrochloride is converted to the N-Boc-protected methyl ester by treatment with di-tert-butyl dicarbonate (1.15 molar equivalents) in dichloromethane/methanol (9:1 v/v) with triethylamine (2.0 molar equivalents) at 20–25°C for 6 hours; the protecting group introduction proceeds quantitatively by HPLC area. Selective ester hydrolysis with lithium hydroxide (1.2 molar equivalents) in tetrahydrofuran/water (3:1 v/v) at 0–5°C yields Boc-D-Phe-OH, which is then coupled to H-Pro-Arg(Pbf)-resin or a solution-phase H-Pro-Arg fragment using HBTU (1.1 molar equivalents) with N,N-diisopropylethylamine (2.5 molar equivalents) in N,N-dimethylformamide at 0°C for 15 minutes followed by 2 hours at 20–25°C. Fragment coupling yields for the D-Phe-Pro amide bond are documented in the 85–93% range when the reaction is monitored by HPLC on a C18 column with UV detection at 220 nm. After global deprotection and cleavage from the resin, crude bivalirudin is purified by preparative reversed-phase HPLC using C18 silica and an acetonitrile/water gradient containing 0.1% trifluoroacetic acid, followed by counterion exchange to the acetate salt. The purified API is lyophilized and tested against the USP bivalirudin monograph, which specifies peptide content determination by HPLC, amino acid analysis to confirm the D-Phe:Pro:Arg ratio, and optical rotation limits for enantiomeric verification of the D-Phe residue. Residual trifluoroacetic acid must be controlled below the limit specified in USP general chapter <621> for peptide pharmaceuticals, typically below 0.5% w/w in the final lyophilized powder. Process-scale implementation of this route requires ICH Q7 alignment for peptide API manufacturing, ICH Q11 for starting material justification (the D-Phe-OMe·HCl may be designated as a regulatory starting material if it carries sufficient chiral purity and impurity documentation), and ICH Q3D for elemental impurity control in the final injectable dosage form.

Compliance documentation for all applications of D-Phe-OMe·HCl as a pharmaceutical intermediate is consolidated in the following matrix of governing standards and the corresponding parameter each framework controls.